[
  {
    "doc_id": "PMID_41593683",
    "summary": "[95%CI 0.24-0.36] to 11.42 [95%CI 9.91-13.17]). [95%CI 0.24-0.36] to 11.42"
  },
  {
    "doc_id": "PMID_41543478",
    "summary": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective weight loss agents, with growing evidence suggesting potential benefits in MASH. Secondary outcomes included \u22651-point improvements in the nonalcoholic fatty liver disease activity score, changes in liver histologic features, and the incidence of serious adverse events. The pooled serious adverse event rate for GLP-1RAs was comparable to placebo."
  },
  {
    "doc_id": "PMID_41629827",
    "summary": "Modifiable lifestyle factors, particularly diet, may play a key role in renal health. These findings highlight the potential for dietary interventions that promote overall healthy eating patterns to contribute to the primary prevention of CKD. Not applicable."
  },
  {
    "doc_id": "PMID_41551204",
    "summary": "We aim to evaluate the effectiveness of the novel real-time continuous glucose monitoring (rtCGM) system \" This prospective, open-label, randomized controlled trial included 172 patients with T2D from the Fatebenefratelli-Sacco Hospital in Milan. Participants were randomized into 2 groups: 86 patients received the After 6 months, the The use of the NCT07089979."
  },
  {
    "doc_id": "PMID_41592063",
    "summary": "Moderate-to-strong correlations were observed, strongest at Week 4 (Rho = 0.65, 95% CI, 0.52-0.75, P < .001). Moderate-to-strong correlations were observed, strongest at Week 4 (Rho = 0.65, 95% CI, 0.52-0.75, P < .001). Our findings support the use of PEth as an objective measure of heavy drinking days in a clinical setting."
  },
  {
    "doc_id": "PMID_41540107",
    "summary": "PCI was superior in 29.2% of comparisons, medical therapy in 23.3%, and the two groups were tied in 47.5%, resulting in a win ratio of 1.25 in favor of PCI (95% confidence interval (CI) 1.01-1.56, P = 0.043). PCI was superior in 29.2% of comparisons, medical therapy in 23.3%, and the two groups were tied in 47.5%, resulting in a win ratio of 1.25 in favor of PCI (95% confidence interval (CI) 1.01-1.56, P = 0.043). ClinicalTrials.gov"
  },
  {
    "doc_id": "PMID_41629143",
    "summary": "SGLT2 inhibitorsTheir mechanism combines moderate osmotic natriuresis, selective reduction of extracellular volume, renal protection, and minimal neurohormonal activation. Evidence suggests that SGLT2i may reduce chronic diuretic requirements, improve renal function, and provide additional cardiovascular protection."
  },
  {
    "doc_id": "PMID_41654775",
    "summary": "The favorable changes observed in LVEF, LVGLS, and NT-proBNP parameters suggest that dapagliflozin may be considered a potential cardioprotective agent and incorporated into preventive strategies against chemotherapy-related cardiotoxicity in diabetic patients. These hypothesis-generating findings require confirmation in larger randomized trials powered for clinical endpoints with longer follow-up. The favorable changes observed in LVEF, LVGLS, and NT-proBNP parameters suggest that dapagliflozin may be considered a potential cardioprotective agent and incorporated into preventive strategies against chemotherapy-related cardiotoxicity in diabetic patients."
  },
  {
    "doc_id": "PMID_41609932",
    "summary": "There were significant main effects of bupropion dosage level (low, medium, or high) (p = 0.04) and number of falls during the six months prior to study entry (p < 0.001). There were significant main effects of bupropion dosage level (low, medium, or high) (p = 0.04) and number of falls during the six months prior to study entry (p < 0.001). Study fall rates extrapolated out to the number of falls per year of treatment for subgroups distinguished by dosage level and prior falls ranged from 1.39 falls/year (no history of falls, low dosage bupropion) to 12.32 falls/year (3 + falls during the 6 months prior to study entry, high dosage bupropion)."
  },
  {
    "doc_id": "PMID_41553512",
    "summary": "Statin use increased from 22.3% to 82.4%, ACEi/ARB/ARNI from 58.2% to 89.3%, beta-blockers from 44.8% to 86.8%, and MRAs from 23.4% to 67.3%. Independent adverse outcome predictors were low hemoglobin, high HbA1c, impaired renal function, and reduced LVEF. Independent adverse outcome predictors were low hemoglobin, high HbA1c, impaired renal function, and reduced LVEF."
  },
  {
    "doc_id": "PMID_41572076",
    "summary": "The behavioural tests were performed after eight weeks of inducing diabetes. Real-time polymerase chain reaction was used to carry out expression analysis. Real-time polymerase chain reaction was used to carry out expression analysis."
  },
  {
    "doc_id": "PMID_41623057",
    "summary": "The mean age was 67.6\u00b110.2 years, 24% were female, and 29% had diabetes. The mean age was 67.6\u00b110.2 years, 24% were female, and 29% had diabetes. At 1 year, patients with focal coronary artery disease reported less angina than those with diffuse coronary artery disease (Seattle Angina Questionnaire angina frequency score, 95.3\u00b19.9 versus 92.5\u00b115.0; In patients with flow-limiting coronary artery disease, the presence of focal disease defined by high PPG was associated with greater symptomatic relief at 1 year compared with diffuse disease (low PPG)."
  },
  {
    "doc_id": "PMID_41574965",
    "summary": "Lorcaserin reduced total body weight (time*treatment, p = 0.004). Lorcaserin reduced total body weight (time*treatment, p = 0.004). Adjusted delta and endpoint comparisons showed reductions in total body (p = 0.031) and abdominal fat mass (p = 0.002)."
  },
  {
    "doc_id": "PMID_41539381",
    "summary": "Seasonal peaks are consistently associated with excess hospitalizations and mortality. Systemic inflammation, plaque destabilization, metabolic imbalance, endothelial dysfunction, and pro-thrombotic activation collectively contribute to acute coronary syndromes, myocarditis, arrhythmias, and acute or worsening heart failure. Randomized trials and meta-analyses consistently support vaccination as a powerful preventive tool, associated with a 25-37% reduction in major adverse cardiovascular events and mortality, with benefits comparable to established cardioprotective therapies."
  },
  {
    "doc_id": "PMID_41625815",
    "summary": "Psychological measures improved, with PSS scores dropping from 17.7 \u00b1 3.2 to 9.80 \u00b1 1.67 in YG and 16.0 \u00b1 2.3 to 9.53 \u00b1 1.48 in CYG; smaller reductions occurred in GH and Control. Psychological measures improved, with PSS scores dropping from 17.7 \u00b1 3.2 to 9.80 \u00b1 1.67 in YG and 16.0 \u00b1 2.3 to 9.53 \u00b1 1.48 in CYG; smaller reductions occurred in GH and Control. The combined yoga and gastro\u2011hepatic pack (CYG) intervention outperformed either alone in reducing stress and improving glycemic control in type 2 diabetes."
  },
  {
    "doc_id": "PMID_41557987",
    "summary": "Adherence was measured semiannually for 3 years using a validated three-item scale (0-100, lowest to highest adherence) in a substudy (N = 1,739). Analyses included evaluation of adherence over time and testing treatment group differences in adherence and in the association between adherence and primary (HbA1c \u22657.0%) and secondary (HbA1c >7.5%) glycemic outcomes. Medication adherence was consistently high in GRADE."
  },
  {
    "doc_id": "PMID_41533371",
    "summary": "ClinicalTrials.gov Identifier: NCT03609944. ClinicalTrials.gov"
  },
  {
    "doc_id": "PMID_41550872",
    "summary": "The safety profiles differ significantly, particularly regarding hypotension risk with ARNI and renal protection with SGLT2i. The choice of regimen should be individualized based on patient priorities, comorbidities, and safety tolerability profiles. The safety profiles differ significantly, particularly regarding hypotension risk with ARNI and renal protection with SGLT2i."
  }
]